NO20014341L - Opplösning av flerumettede fettsyrer og derivater derav ved dannelse av inklusjonssammensetninger med <gamma>-syklodekstrin ogbruk derav i farmasöytiske, kosmetiske eller matsammensetninger - Google Patents

Opplösning av flerumettede fettsyrer og derivater derav ved dannelse av inklusjonssammensetninger med <gamma>-syklodekstrin ogbruk derav i farmasöytiske, kosmetiske eller matsammensetninger

Info

Publication number
NO20014341L
NO20014341L NO20014341A NO20014341A NO20014341L NO 20014341 L NO20014341 L NO 20014341L NO 20014341 A NO20014341 A NO 20014341A NO 20014341 A NO20014341 A NO 20014341A NO 20014341 L NO20014341 L NO 20014341L
Authority
NO
Norway
Prior art keywords
compositions
fatty acids
polyunsaturated fatty
cosmetic
dissolution
Prior art date
Application number
NO20014341A
Other languages
English (en)
Other versions
NO20014341D0 (no
Inventor
Florence Pilard Djedaini
Bruno Perly
Jean-Pierre Dalbiez
Quitterie Michon
Beatrice Rousseau
Pascale Barrier
Original Assignee
Sea Oil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sea Oil filed Critical Sea Oil
Publication of NO20014341L publication Critical patent/NO20014341L/no
Publication of NO20014341D0 publication Critical patent/NO20014341D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/738—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Polymers & Plastics (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

Hensikten med foreliggende oppfinnelse er en vandig oppløsning som omfatter minst et oljeaktig stoff valgt fra flerumettede fettsyrer og salter, estere og triglyserider av flerumettede fettsyrer, hvor de nevnte stoff(er) er i form av et inklusjonskompleks i y-syklodekstrin.Det oljeaktige stoffet(ene) kan være valgt fra arakidonsyre (AA), eikosapentaensyre (EPA), dokosaheksaensyre (DHA) og triglyserider derav såvel som fra fiskeoljer.
NO20014341A 1999-03-09 2001-09-06 Opplösning av flerumettede fettsyrer og derivater derav ved dannelse av inklusjonssammensetninger med <gamma>-syklodekstrin ogbruk derav i farmasöytiske, kosmetiske eller matsammensetninger NO20014341D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9902881A FR2790758A1 (fr) 1999-03-09 1999-03-09 Solubilisation d'acides gras polyinsatures et de leurs derives par formation de complexes d'inclusion avec une cyclodextrine et leur utilisation dans des compositions pharmaceutiques, cosmetiques ou alimentaires
PCT/FR2000/000560 WO2000053637A1 (fr) 1999-03-09 2000-03-07 COMPLEXES D'INCLUSION D'ACIDES GRAS POLYINSATURES ET DE LEURS DERIVES AVEC LA η-CYCLODEXTRINE

Publications (2)

Publication Number Publication Date
NO20014341L true NO20014341L (no) 2001-09-06
NO20014341D0 NO20014341D0 (no) 2001-09-06

Family

ID=9542970

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014341A NO20014341D0 (no) 1999-03-09 2001-09-06 Opplösning av flerumettede fettsyrer og derivater derav ved dannelse av inklusjonssammensetninger med <gamma>-syklodekstrin ogbruk derav i farmasöytiske, kosmetiske eller matsammensetninger

Country Status (6)

Country Link
EP (1) EP1165620A1 (no)
JP (1) JP2002539138A (no)
CA (1) CA2366719A1 (no)
FR (1) FR2790758A1 (no)
NO (1) NO20014341D0 (no)
WO (1) WO2000053637A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10253042A1 (de) 2002-11-14 2004-06-03 Wacker-Chemie Gmbh Kosmetische Zubereitung enthaltend einen Komplex aus Cyclodextrin und Vitamin F
ES2209658B1 (es) * 2002-12-05 2005-10-01 Proyecto Empresarial Brudy, S.L. Utilizacion del acido docosahexaenoico como principio activo para el tratamiento de la lipodistrofia.
FR2850040B1 (fr) * 2003-01-20 2005-03-11 Centre Nat Rech Scient Systemes pour microencapsulation et leurs applications
US7335386B2 (en) 2003-07-30 2008-02-26 Gerneral Mills, Inc. Method for preventing acrylamide formation in food products and food intermediates
US20040180125A1 (en) * 2003-03-11 2004-09-16 Plank David W. Cyclodextrin-containing compositions and methods
US7105195B2 (en) 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
CA2529735C (en) * 2003-06-20 2012-07-10 Mochida Pharmaceutical Co., Ltd. Eicosapentaenoic acid for preventing or treating varicose veins of lower extremities
EP2049083A2 (en) * 2006-12-27 2009-04-22 Cargill, Incorporated Stabilisation by preparing cyclodextrin inclusion complexes
FR2915901A1 (fr) * 2007-05-07 2008-11-14 In Cyclo Soc Par Actions Simpl Composition homogene et stable, riche en substances oleagineuses a base d'un produit laitier, son procede de preparation et ses utilisations.
GB0710439D0 (en) * 2007-05-31 2007-07-11 Uni I Oslo Oral dosage form
GB0808479D0 (en) * 2008-05-09 2008-06-18 Uni I Oslo Topical compositions
FR3048177B1 (fr) * 2016-02-25 2020-10-30 Fabre Pierre Dermo Cosmetique Composition cosmetique biphase et son utilisation par application topique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5813541A (ja) * 1981-07-16 1983-01-26 Kureha Chem Ind Co Ltd エイコサペンタエン酸又はドコサヘキサエン酸のシクロデキストリン包接化合物
JPS5941395A (ja) * 1982-09-01 1984-03-07 マルハ株式会社 魚油類の安定化方法
JPS6034156A (ja) * 1983-08-08 1985-02-21 Hayashibara Biochem Lab Inc エイコサペンタエン酸包接化合物及びこれを含有した飲食物
IT1243192B (it) * 1990-08-09 1994-05-24 Staroil Ltd Complessi di acidi grassi polinsaturi a lunga catena e di loro derivati, con ciclodestrine
JPH0725816A (ja) * 1993-07-08 1995-01-27 Yoshihisa Matsuda ポリエン酸類の包接化合物

Also Published As

Publication number Publication date
EP1165620A1 (fr) 2002-01-02
CA2366719A1 (fr) 2000-09-14
FR2790758A1 (fr) 2000-09-15
WO2000053637A1 (fr) 2000-09-14
NO20014341D0 (no) 2001-09-06
JP2002539138A (ja) 2002-11-19

Similar Documents

Publication Publication Date Title
Calder Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases
NO991635D0 (no) Farmas°ytisk preparat omfattende eikospentaensyre og/eller stearidonsyre
EP1537069A4 (en) ANALOGUE OF OMEGA-3 PUFA DERIVED LIPID MEDIATORS AND METHOD OF USE
NO20014341L (no) Opplösning av flerumettede fettsyrer og derivater derav ved dannelse av inklusjonssammensetninger med &lt;gamma&gt;-syklodekstrin ogbruk derav i farmasöytiske, kosmetiske eller matsammensetninger
Igarashi et al. Dietary n-6 PUFA deprivation for 15 weeks reduces arachidonic acid concentrations while increasing n-3 PUFA concentrations in organs of post-weaning male rats
KR940018090A (ko) 트리글리세라이드
NO20026093L (no) Terapeutiske kombinasjoner av fettsyrer
EA200100895A1 (ru) Незаменимые жирные кислоты для предотвращения сердечно-сосудистых приступов
KR940018091A (ko) 불포화 지방산을 포함하는 처방
DE60212786D1 (de) Verwendung von polyungesättigten Fettsäuren zur primären Vorbeugung von kardiovaskulären Anfällen
IL210233A (en) Formulation of omega-3 fatty acid containing epa and dha and no other active ingredients other than omega-3 fatty acids
EP2415360A3 (en) Use of DPA(n-6) oils in infant formula
JP2013508296A5 (no)
EP1698685A4 (en) FAT COMPOSITION
JP2008528742A (ja) クリプテコディニウム属からの抗酸化抽出物の製造および使用
Leray Introduction to lipidomics: from bacteria to man
RU2010103038A (ru) Композиции для персонального ухода, обладающие ослабленным раздражающим действием на глаза
TW360545B (en) Dermatologic preparation
NO20071180L (no) Delta 6-desaturase-gener og anvendelser derav
Calder Comment on Christiansen et al.: When food met pharma
JP2023523020A (ja) イソチオシアネートを安定化するための組成物
ES2839877T3 (es) Combinación de un retinoide y un diol y éster de ácido graso poliinsaturado
KR960009875A (ko) 어취의 마스킹법
EP4327870A3 (en) Method for improving white matter integrity in hyperphenylalaninemia and phenylketonuria patients
TH63561A (th) โคเอนไซม์ q และ epa หรือกรดไขมันที่จำเป็นอื่น